Chiesi Global Rare Diseases, a Chiesi Farmaceutici SpA business unit, has signed a co-development agreement with Aliada Therapeutics Inc.

Hebecell Corp. and Logomix Inc. have established a strategic partnership to research and develop gene-edited natural killer (NK) cells and discover genetic modifications that can create next-generation designer NK cells. Under the agreement, Logomix provides genome editing capabilities to Hebecell for development of next-generation designer Protonk cells.

Impact Biotech Ltd. has entered into an agreement with Maastricht University to collaborate on research focused on eye treatment to arrest the progression of pathological myopia, also known as myopic macular degeneration. The project will use Impact's padeliporfin vascular targeted photodynamic (VTP) therapy platform.

Celmatix Inc. and Aché Laboratórios Farmacéuticos SA will study the role of melatonin receptors and their agonists in polycystic ovary syndrome (PCOS). The two companies announced a collaboration, with a separate license and development agreement upon conclusion of the research.

Novaccess Global Inc. has signed a letter of intent and formed a partnership with BCN Biosciences LLC to expand its immunotherapy platform. Utilizing BCN’s small-molecule drug BCN-057, Novaccess Global has begun the development of a fourth generation of its novel brain tumor immunotherapy TLR-AD-1, targeting glioblastoma.

Golgi Neurosciences srl and Breye Therapeutics ApS have established a collaboration to develop Golgi’s P2X7 receptor antagonist program for retinal disorders. The companies have now closed the transfer of the P2X7 receptor antagonist program, which seeks to reduce nerve damage and inflammation in retinal disease and advance development of innovative oral small-molecule therapeutics for retinal disorders.

As quicker, more accurate ways to detect dementia becomes ever more urgent, Cumulus Neuroscience Ltd. has teamed up with the Universities of Bath and Bristol in the U.K. to further develop the Fastball electroencephalogram (EEG) test, a diagnostic test for earlier detection of Alzheimer’s dementia. With one in three people born in the U.K. today likely to develop dementia at some point in their lives, early diagnosis and treatment are essential for them to plan for their future.

Recludix Pharma Inc. has entered into a strategic collaboration with Sanofi SA to develop and commercialize first-in-class oral small-molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.

Saniona AB has established a new research collaboration with Astronautx Ltd. in Alzheimer’s disease. The aim of the collaboration is to identify new treatments for Alzheimer’s disease and other neurodegenerative conditions by modulating a novel, undisclosed ion channel target. The research collaboration will use Saniona’s proprietary platform, Ionbase, for the modulation of ion channels.